Literature DB >> 20413099

Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay.

Lars Dölken1, Georg Malterer1, Florian Erhard2, Sheila Kothe1, Caroline C Friedel2, Guillaume Suffert3, Lisa Marcinowski1, Natalie Motsch4, Stephanie Barth4, Michaela Beitzinger5, Diana Lieber1, Susanne M Bailer1, Reinhard Hoffmann6, Zsolt Ruzsics1, Elisabeth Kremmer7, Sébastien Pfeffer3, Ralf Zimmer2, Ulrich H Koszinowski1, Friedrich Grässer4, Gunter Meister5, Jürgen Haas8.   

Abstract

The mRNA targets of microRNAs (miRNAs) can be identified by immunoprecipitation of Argonaute (Ago) protein-containing RNA-induced silencing complexes (RISCs) followed by microarray analysis (RIP-Chip). Here we used Ago2-based RIP-Chip to identify transcripts targeted by Kaposi's sarcoma-associated herpesvirus (KSHV) miRNAs (n = 114), Epstein-Barr virus (EBV) miRNAs (n = 44), and cellular miRNAs (n = 2337) in six latently infected or stably transduced human B cell lines. Of the six KSHV miRNA targets chosen for validation, four showed regulation via their 3'UTR, while two showed regulation via binding sites within coding sequences. Two genes governing cellular transport processes (TOMM22 and IPO7) were confirmed to be targeted by EBV miRNAs. A significant number of viral miRNA targets were upregulated in infected cells, suggesting that viral miRNAs preferentially target cellular genes induced upon infection. Transcript half-life both of cellular and viral miRNA targets negatively correlated with recruitment to RISC complexes, indicating that RIP-Chip offers a quantitative estimate of miRNA function. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413099     DOI: 10.1016/j.chom.2010.03.008

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  109 in total

1.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

Review 2.  Diverse virus-host interactions influence RNA-based regulation during γ-herpesvirus infection.

Authors:  Lisa M Kronstad; Britt A Glaunsinger
Journal:  Curr Opin Microbiol       Date:  2012-06-09       Impact factor: 7.934

Review 3.  The role of microRNAs in Epstein-Barr virus latency and lytic reactivation.

Authors:  Eleonora Forte; Micah A Luftig
Journal:  Microbes Infect       Date:  2011-07-28       Impact factor: 2.700

4.  Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression.

Authors:  Aron R Marquitz; Anuja Mathur; Kathy H Y Shair; Nancy Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

Review 5.  EBV Noncoding RNAs.

Authors:  Rebecca L Skalsky; Bryan R Cullen
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 6.  Viral miRNAs and immune evasion.

Authors:  Isaac W Boss; Rolf Renne
Journal:  Biochim Biophys Acta       Date:  2011-07-05

7.  The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1.

Authors:  Nathan Ross; Maher K Gandhi; Jamie P Nourse
Journal:  Am J Blood Res       Date:  2013-08-19

8.  Non-inhibited miRNAs shape the cellular response to anti-miR.

Authors:  John R Androsavich; B Nelson Chau
Journal:  Nucleic Acids Res       Date:  2014-05-07       Impact factor: 16.971

Review 9.  Multiple functions are mediated by the miRNAs of Epstein-Barr virus.

Authors:  Malika Kuzembayeva; Mitchell Hayes; Bill Sugden
Journal:  Curr Opin Virol       Date:  2014-05-10       Impact factor: 7.090

10.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.